EP1406600A4 - COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF TUBULIN BINDING AGENTS FOR THE TREATMENT OF EYE DISEASES - Google Patents

COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF TUBULIN BINDING AGENTS FOR THE TREATMENT OF EYE DISEASES

Info

Publication number
EP1406600A4
EP1406600A4 EP02756487A EP02756487A EP1406600A4 EP 1406600 A4 EP1406600 A4 EP 1406600A4 EP 02756487 A EP02756487 A EP 02756487A EP 02756487 A EP02756487 A EP 02756487A EP 1406600 A4 EP1406600 A4 EP 1406600A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
binding agents
ocular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02756487A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1406600A1 (en
Inventor
David Sherris
Mark Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxi Gene Inc
Original Assignee
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxi Gene Inc filed Critical Oxi Gene Inc
Publication of EP1406600A1 publication Critical patent/EP1406600A1/en
Publication of EP1406600A4 publication Critical patent/EP1406600A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP02756487A 2001-07-13 2002-07-15 COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF TUBULIN BINDING AGENTS FOR THE TREATMENT OF EYE DISEASES Withdrawn EP1406600A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US386227P 2001-07-13
US37784502P 2002-05-03 2002-05-03
US37755602P 2002-05-03 2002-05-03
US37784702P 2002-05-03 2002-05-03
US377845P 2002-05-03
US377847P 2002-05-03
US377556P 2002-05-03
PCT/US2002/022449 WO2003006002A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Publications (2)

Publication Number Publication Date
EP1406600A1 EP1406600A1 (en) 2004-04-14
EP1406600A4 true EP1406600A4 (en) 2007-06-06

Family

ID=32034390

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02756487A Withdrawn EP1406600A4 (en) 2001-07-13 2002-07-15 COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF TUBULIN BINDING AGENTS FOR THE TREATMENT OF EYE DISEASES

Country Status (8)

Country Link
EP (1) EP1406600A4 (it)
JP (2) JP2004536847A (it)
KR (1) KR20040030042A (it)
CN (1) CN1527704B (it)
CA (1) CA2453442C (it)
NZ (1) NZ575466A (it)
WO (1) WO2003006002A1 (it)
ZA (1) ZA200400210B (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (ja) * 2003-04-09 2007-11-07 日信工業株式会社 炭素繊維複合材料およびその製造方法
WO2011003080A1 (en) * 2009-07-02 2011-01-06 Oxigene, Inc. Combretastatins for prevention of posterior capsule opacification
ES2545340T3 (es) 2009-08-27 2015-09-10 Bionomics Limited Terapia de la combinación para el tratamiento de enfermedades proliferativas
CA2771807A1 (en) * 2009-08-27 2011-03-03 Bionomics Limited Treatment of macular degeneration
JP6124227B2 (ja) * 2012-08-02 2017-05-10 アムリル・アクチェンゲゼルシャフトＡｍｒｉｌ Ａｇ ナノカーボンを含有する天然ゴム
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048591A1 (en) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Combinations for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
WO2002022626A1 (en) * 2000-09-14 2002-03-21 Bristol-Myers Squibb Company Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
CA2314238C (en) * 1998-01-09 2008-09-02 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of combretastatin a-4 prodrugs and trans-isomers thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048591A1 (en) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Combinations for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
WO2002022626A1 (en) * 2000-09-14 2002-03-21 Bristol-Myers Squibb Company Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRIGGS J ET AL: "Targeting tumour vasculature: the development of combretastatin A4.", THE LANCET ONCOLOGY FEB 2001, vol. 2, no. 2, February 2001 (2001-02-01), pages 82 - 87, XP005063056, ISSN: 1470-2045 *
See also references of WO03006002A1 *

Also Published As

Publication number Publication date
CN1527704A (zh) 2004-09-08
CA2453442A1 (en) 2003-01-23
CA2453442C (en) 2011-02-01
WO2003006002A8 (en) 2004-05-27
KR20040030042A (ko) 2004-04-08
CN1527704B (zh) 2011-05-18
EP1406600A1 (en) 2004-04-14
JP2009132738A (ja) 2009-06-18
NZ575466A (en) 2011-01-28
JP2004536847A (ja) 2004-12-09
ZA200400210B (en) 2005-06-29
WO2003006002A1 (en) 2003-01-23
WO2003006002A9 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
IL176227A0 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
EP1575480A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
EP1578367A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1572116A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1576137A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
HU0002963D0 (en) Methods and compositions for treating diseases and conditions of the eye field of invention
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
HUP0104963A3 (en) Compositions for the treatment of skin diseases
EP1416795A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES OF MITOCHONDRIA
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2002366028A1 (en) Use of fk506 and analogues for treating allergic diseases
EP1472273A4 (en) COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
EP1440080A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATION DISORDERS INVOLVING THE 20750

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1064941

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070509

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20070503BHEP

Ipc: A61K 31/09 20060101AFI20070503BHEP

17Q First examination report despatched

Effective date: 20090806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120731

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1064941

Country of ref document: HK